DEA Classifies Tramadol as a Schedule IV Controlled Substance

Krystle Vermes
Published Online: Thursday, August 21, 2014
Follow Pharmacy_Times:
As of August 18, 2014, the Drug Enforcement Administration (DEA) has officially placed tramadol, a centrally acting opioid analgesic, into schedule IV of the Controlled Substances Act.
 
In the past, it was widely believed that tramadol had a better safety profile than other opioid analgesics. Now that the drug has been deemed a Schedule IV substance, however, health care professionals may be less likely to prescribe it to patients for pain.
 
Within the first 2 years of the drug’s approval for use in the United States, between 2 to 3 patients out of every 100,000 were abusing tramadol, experts found. Researchers also discovered that patients were susceptible to suffering from opioid-like withdrawal symptoms after stopping tramadol treatment. In fact, 40% of the adverse effects associated with tramadol are linked to discontinuation of the painkiller.
 
In 2010 alone, more than 16,000 visits to the emergency room were documented as resulting from the use of tramadol for non-medial purposes.
 
This past June, the United Kingdom decided to place tramadol under strict restrictions. Several states have been implementing laws of their own to schedule tramadol as a controlled substance. As a result, the level of exposure to the drug has dropped in those areas.
 
Now that the DEA has stepped in, there is potential for the amount of tramadol exposure to decrease across the nation as a whole.
 
“As confirmed by the association, current distributors of tramadol are DEA registrants with existing controlled substance storage that complies with DEA regulations,” the agency explained in its declaration. “The DEA understands that handlers of tramadol may need to make modifications to their current security procedures for compliance. These modifications necessary for security compliance will be a 1-time modification to provide for the appropriate storage, revision of operating procedures, training of staff, and amendments to suspicious order monitoring systems to include customer verifications.”
Related Articles
New research posits that cocaine use quadruples the risk of sudden cardiovascular death among individuals aged 19 to 49 years.
With Pennsylvania pharmacies now authorized to fill third-party naloxone prescriptions and California pharmacies set to dispense naloxone without any prescription at all, more and more pharmacists are providing a critical public pathway to the opioid overdose antidote.
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
When a would-be robber entered a pharmacy in Wyoming with what looked like a real gun, a pharmacist behind the counter reached for his firearm and injured the suspect by shooting him, according to the Wyoming Tribune Eagle.
Latest Issues
$auto_registration$